Cite
HARVARD Citation
Guo, M. et al. (2021). Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer. Touch reviews in oncology & haematology. 17 (1), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Guo, M. et al. (2021). Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer. Touch reviews in oncology & haematology. 17 (1), p. . [Online].